CVT-313

製品コードS6537 バッチS653702

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₀H₂₈N₆O₃

分子量

400.47

CAS No.

199986-75-9

Solubility (25°C)*

体外

DMSO

80 mg/mL (199.76 mM)

Ethanol

80 mg/mL (199.76 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	4.000mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	2.000mg/ml (4.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	CVT-313 is a potent CDK2 inhibitor with an IC50 of 0.5 microM in vitro. It has no effect on other, nonrelated ATP-dependent serine/threonine kinases.
in vitro	In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product is inhibited, and progression through the cell cycle is arrested at the G1/S boundary. The growth of mouse, rat, and human cells in culture is also inhibited by this compound with the IC50 for growth arrest ranging from 1.25 to 20 μM. This chemical inhibits Rb hyperphosphorylation^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	MRC-5 cells
	濃度	12.5 μM
	反応時間	24 h
	実験の流れ	--
動物実験	動物モデル	Rat carotid artery model of restenosis
	投薬量	0.025, 0.25, 0.75, 1.25 mg/kg
	投与方法	intraluminal

参考

https://pubmed.ncbi.nlm.nih.gov/9360999/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer [ Cell Rep Med, 2025, S2666-3791(25)00231-9]	PubMed: 40449480
The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages [ Cancer Cell Int, 2023, 10.1186/s12935-023-03079-2]	PubMed: 37865750
The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages [ Cancer Cell Int, 2023, 23(1):248]	PubMed: 37865750
Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer [ Cell Rep, 2022, 40(7):111218]	PubMed: 35977518
Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway [ Biomedicines, 2022, 10(8)2012]	PubMed: 36009559
Dbf4-Cdc7 (DDK) InhibitorPHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway [ Biomedicines, 2022, 10(8)2012]	PubMed: 36009559
Genetic vulnerabilities upon inhibition of DNA damage response [ Nucleic Acids Res, 2021, gkab643]	PubMed: 34320214
Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer [ Cancer Sci, 2021, 112(12):4909-4919]	PubMed: 34632667

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。